1,627 research outputs found
Diagnostic and prognostic studies in Hodgkin's lymphoma with special reference to the elderly
No full textThe introduction of modem staging procedures, and developments in both radiotherapy and chemotherapy have significantly contributed to improved response and survival rates in Hodgkin's lymphoma (HL) during the last decades. However, still a substantial proportion of patients succumb from tumour progression and/or complications related to diagnostic procedures and/or treatment. The presently identified risk factor profiles do not allow accurate tailoring of treatment, especially in the elderly patient population. The overriding goal of the present study was to improve clinical management of HL patients, particularly in the elderly.Individuals with lymphadenopathy and accessible lymph nodes (n=103) were prospectively studied first by fine-needle aspiration cytology (FNAC) and then by histological examination of a biopsy from the same lymph node site. The diagnoses were concordant in 74%. In 10% a major discordance between FNAC and histopathologic diagnoses was found and in 16% minor discordances without clinical impact were recorded. Since the treatment decisions were based on both clinical and FNAC/histopathology data the discrepancies between FNAC and histopathology had only limited impact on the overall clinical strategy. FNAC is an accurate and safe method in the diagnosis of lymphomas when the cytologic diagnosis is corroborated by immunocytochemistry. In certain risk patients FNAC may well be used as a single method. Concerns about the increasing use of FNAC for primary diagnosis include certain shortcomings in lymphoma classification and loss of archival tissue for complementary analyses, reclassification and research purposes. Freezing of cytospin material or cell pellets may, however, allow certain future analyses.The clinical value of routine bone scintigraphy in untreated HL patients was limited. Bone involvement was a rare finding (7/183; 4%). Only one patient received additional local radiotherapy based on the scintigraphic findings. Bone pain was a good predictor of osseous involvement. Performed follow-up scintigraphies showed regression of the initially observed abnormalities suggesting scintigraphy to be a cost-effective alternative method to assess response to treatment in patients with bone involvement.Based on a vaccination algorithm including repeated 23-valent pneumococcal vaccinations, a significant response was found on three vaccination occasions in splenectomized patients with HL (n=208), autoimmune hemolytic anemia (n= 15), and immune thrombocytopenic purpura (n=60) as well as individuals who underwent splenectomy due to splenic rupture caused by trauma (n=28). The observed case morbidity and fatality rates in the HL cohort were lower as compared to those reported in most studies supporting the value of revaccination and other preventive measures such as education of patients and health care professionals.There is a great heterogeneity in outcome in elderly (>60 years) HL patients. Many factors contribute to a decreased relative dose intensity of chemotherapy which is strongly associated with a dismal prognosis in this patient population. ABVD-based chemotherapy appears superior to MOPP variants. Long-term survival can be achieved even following minimal chemotherapy. There is great lack of apt predictors of prognosis as well as alternative treatment modalities in elderly HL patients. Parental longevity was not associated with improved outcome in an elderly HL cohort. Neither was there a significant difference in the distribution of causes of death with reference to parental lifespan.Serum levels of IL-10 and sCD30 added prognostic information to that achieved by conventional predictors of prognosis, suggesting that these markers should be validated in large prospective trials.List of scientific papersI. Landgren O, Porwit macDonald A, Tani E, Czader M, Grimfors G, Skoog L, Ost A, Wedelin C, Axdorph U, Svedmyr E, Bjorkholm M (2002). A prospective comparison of fine-needle aspiration cytology and histopathology in the diagnosis and classification of lymphomas. [Submitted]II. Landgren O, Axdorph U, Jacobsson H, Johansson B, Grimfors G, Bjorkholm M (2000). Routine bone scintigraphy is of limited value in the clinical assessment of untreated patients with Hodgkins disease. Med Oncol. 17(3): 174-8. https://pubmed.ncbi.nlm.nih.gov/10962526III. Landgren O, Bkorkholm M, Bossen Konradsen H, Soderquist M, Nilsson B, Gustavsson A, Axdorph U, Kalin M, Grimfors G (2002). A prospective study on antibody response to repeated vaccinations with pneumococcal capsular polysacharide in splenectomized individuals with special reference to Hodgkins lymphoma. [Manuscript]IV. Landgren O, Algernon C, Axdorph U, Nilsson B, Wedelin C, Porwit MacDonald A, Grimfors G, Bjorkholm M (2002). Hodgkins lymphoma in the elderly with special reference to type and intensity of chemotherapy in relation to prognosis. [Submitted]V. Landgren O, Askling J, Dickman PW, Osby E, Axdorph U, Ekbom A, Bjorkholm M (2002). Parental longevity and survival in elderly patients with Hodgkins lymphoma. Haematologica. 87(6): 595-601. https://pubmed.ncbi.nlm.nih.gov/12031915VI. Axdorph U, Sjoberg J, Grimfors G, Landgren O, Porwit-MacDonald A, Bjorkholm M (2000). Biological markers may add to prediction of outcome achieved by the International Prognostic Score in Hodgkins disease. Ann Oncol. 11(11): 1405-11. https://pubmed.ncbi.nlm.nih.gov/11142480</p
Dr. F.S.J. Ledgister, CAU, August 2011
No full textThis video is a conversation with Dr. F.S.J. Ledgister. Dr. Ledgister talks about his book, "Only West Indians: Creole Nationalism in the British West Indies". Ola Ijimayowa, AUC Woodruff Library, is the interviewer
Dr. Abi Adegboye Awomolo, CAU, August 2011
No full textThis video is a conversation with Dr. Abi Adegboye Awomolo. Dr. Abi Awomolo talks about her book, "Wanna B Prez?: 10 Life Strategies From President Barack Obama's Journey to the White House". Ola Ijimayowa, AUC Woodruff Library, is the interviewer
Sundown \u27Possum (As told to the author by Ola MAupin, Lillie Westmoreland, Maud Vincent and reiterated by Jack Maupin)
No full textSundown \u27Possum (As told to the author by Ola Maupin, Lillie Westmoreland, Maud Vincent and reiterated by Jack Maupin)
Mary Bursell Maupi
Clin Cancer Res
No full textOver the past few years, the management of multiple myeloma has changed. We have new guidelines regarding how to set the diagnosis, when to initiate therapy, and how to monitor treatment response. In 2014, the updated International Myeloma Working Group (IMWG) diagnostic criteria changed the definition of multiple myeloma from being a disease defined by symptoms to a disease defined by biomarkers. Today, modern combination therapies have reported up to 60% to 80% of patients reaching a complete response. As a logical and necessary step forward, investigators have explored strategies to detect minimal residual disease (MRD) and its correlation with clinical outcomes. Recent meta-analysis data show that MRD negativity is associated with longer progression-free survival and overall survival. In 2016, the updated IMWG response criteria include MRD as the deepest level of treatment response in multiple myeloma. Simultaneously, we are still quite behind in our understanding of the heterogeneous biology of multiple myeloma and its implications for therapy. Emerging DNA sequencing data show that newly diagnosed multiple myeloma patients have a broad range of mutations, which are distributed unevenly in multiple parallel subclones already present at diagnosis. To move beyond the ill-defined category of "high-risk multiple myeloma," which confers to approximately 25% of all newly diagnosed patients, prospective studies are needed to dissect tumor biology and define multiple myeloma subtypes, and, based on biology, seek to define rational therapies for individual subtypes. This article discusses novel insights and gives perspectives on diagnosis and MRD monitoring and future directions for prognosis and clinical management of multiple myeloma. Clin Cancer Res; 22(22); 5428-33. \ua92016 AACR SEE ALL ARTICLES IN THIS CCR FOCUS SECTION, "MULTIPLE MYELOMA MULTIPLYING THERAPIES".P30 CA008748/CA/NCI NIH HHSUnited States/P50 CA186781/CA/NCI NIH HHSUnited States/U01 FD005642/FD/FDA HHSUnited States/U01 OH011475/OH/NIOSH CDC HHSUnited States
Clin Cancer Res
No full textSince the mid-1990s, the multiple myeloma treatment landscape has evolved considerably, which has led to improved patient outcomes and prolonged survival. In addition to discovering new, targeted agents or treatment regimens, the identification and validation of biomarkers has the potential to further improve patient outcomes. The International Staging System relies on a number of biochemical parameters to stratify patients into risk categories. Other biologically relevant markers that are indicative of inherited genetic variation (e.g., single-nucleotide polymorphisms) or tumor-acquired genetic events (e.g., chromosomal translocations or mutations) have been studied for their prognostic potential. In patients with high-risk cytogenetics, plasma cells (PC) undergo genetic shifts over time, which may partially explain why high-risk patients relapse and are so difficult to treat. Although novel agents have improved treatment outcomes, identification of markers that will enable clinicians to determine which treatment is most appropriate for high-risk patients following initial diagnosis represents an exciting frontier in the clinical management of multiple myeloma. Biomarkers based on quantitating PCs or factors that are secreted from them (e.g., serum free light chain) may also help to risk-stratify patients with asymptomatic multiple myeloma. Eventually, identification of novel biomarkers may lead to the creation of personalized treatment regimens that are optimized to target clonal PCs that express a specific oncogenomic profile. Although the future is exciting, validation will be necessary before these biologic and molecular beacons can inform decision-making processes in a routine clinical setting.U01 FD005642/FD/FDA HHS/United StatesU01 OH011475/OH/NIOSH CDC HHS/United States2017-08-30T00:00:00Z24270684PMC557617
The blind spots of secularization
No full textAccording to several international surveys Spain is among the western countries with the most negative views of Jews. While quantitative data on the topic accumulates, there is a significant lack of interpretative approaches that might explain the particular Spanish case. This paper presents the background, methodology and major results of a discussion group-based study on antisemitism, which was conducted in Spain in the autumn of 2009. The study identifies and locates in different socio-economic and ideological milieus the range of stereotypical discourses on Jews, Judaism and the Arab–Israeli conflict in Spain. Analysis of the group meetings shows that, despite growing secularization in Spanish society, the central explanatory variable for persisting and resurging antisemitism in this country is still religion in a broad cultural sense.N
comprehensive one
No full texta 2015 Article by Ohuabunwa and OlaThis publication is author by Ohuabunwa and Ola tileed effective learnin
A comparative analysis of Andre Gide's Oedipe and Ola Rotimi's The Gods Are Not to Blame, 2000
No full textAlthough there have been numerous and varied treatments of Oedipus throughout the ages, there is to date no detailed analytical study of myth based on Andre Gides Oedine and Ola Rotimis The Gods Are Not to Blame. This study is a critical analysis of these two dramatic texts, which have been reworked from fifth century Greek tragedy. The principal aim is to compare these two plays taken from different cultures, in an effort to show that they both have a common originSophocles Oedipus the King. Through this comparison, the author wishes to show that each playwright presents Oedipus as a classic, which transcends cultural boundaries, thus making Sophocles drama a classic work in world literature. The study is presented in four chapters. The first chapter serves as an introduction, which deals with the origin of the Oedipus theme and some of the major writers who helped to popularize it. This chapter will also present references, theses and other critical works written on the plays in question. The second and third chapters deal with the plays of each playwright: Oedipe by Andre Gide and The Gods Are Not to Blame by Ola Rotimi. Each chapter will include a brief sketch of the authors life, a resume of the plays, and the development of major and minor characters. The fourth chapter will deal with the similarities and the contrasts in the plays and will also serve as the conclusion
A tale of two Islandoras
No full textThe University of Prince Edward Island (UPEI) and the University of Waterloo (UW) represent two distinct experiences on the road to implementing Islandora – one pioneered its development and the other is launching the digital asset management framework for the first time. The Islandora project is a tool of transformation. At UPEI, it has facilitated learning, enabled and expanded partnerships, funding opportunities, research collaborations, and community engagement, while producing a legacy of platform versions, customized websites, and infrastructure that is unsustainable given existing resources. At UW, it represents a new effort to plan, implement, and scale a presentation and preservation service that leverages the experiences and best practices established by the Islandora community. This presentation will examine the opportunities and challenges that arise when working with Islandora. Focus will be placed on lessons learned, project sustainability and establishing a way forward by contrasting the experiences of first-time and advanced implementers
- …
